Find a Pharmacy
Vertice Login
Menu
close
Info banner
A significant part of the Healthesystems vision is to create a more integrated experience for our customers

Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.

  • FDA Drug Approvals
  • Med Alerts

FDA Drug Approvals

Med Alerts

Veklury® (remdesivir) injection for intravenous use

Approval Date: Oct 2020

Note: new product

Indicated for the treatment of COVID-19 cases requiring hospitalization. Veklury should only be administered in a hospital or healthcare setting capable of providing acute care comparable to inpatient hospital care

Xeljanz® (tofacitinib) oral solution

Approval Date: Sep 2020

Note: new dosage or formulation

A new oral solution formulation, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis

1 2 3 4

Medication Name

Approval Date

Category

Description

Veklury® (remdesivir) injection for intravenous use

Oct 2020

Indicated for the treatment of COVID-19 cases requiring hospitalization. Veklury should only be administered in a hospital or healthcare setting capable of providing acute care comparable to inpatient hospital care

Note: new product

Xeljanz® (tofacitinib) oral solution

Sep 2020

A new oral solution formulation, this drug is indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course juvenile idiopathic arthritis

Note: new dosage or formulation
1 2 3 4
lockmap-markermagnifiercrossmenucross-circle